The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells

This publication has 45 references indexed in Scilit:

• Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation
  Bone Marrow Transplantation, 2005
• CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets
  Leukemia, 2005
• HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
  Blood, 2005
• Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
  Clinical Cancer Research, 2004
• Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation
  European Journal of Immunology, 2004
• Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
  Annual Review of Immunology, 2001
• Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines
  Cellular Immunology, 2000
• Transcriptional Regulation of the Gene Encoding the Human C-type Lectin Leukocyte Receptor AIM/CD69 and Functional Characterization of Its Tumor Necrosis Factor-α-responsive Elements
  Published by Elsevier ,1995
• The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells
  Immunology Today, 1994
• CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA)
  The Lancet, 1964